See more : Varex Imaging Corporation (VREX) Income Statement Analysis – Financial Results
Complete financial analysis of ZIVO Bioscience, Inc. (ZIVO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ZIVO Bioscience, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Wishpond Technologies Ltd. (WISH.V) Income Statement Analysis – Financial Results
- Hydrogen Utopia International PLC (HUI.L) Income Statement Analysis – Financial Results
- PainChek Limited (PCK.AX) Income Statement Analysis – Financial Results
- Li Bao Ge Group Limited (1869.HK) Income Statement Analysis – Financial Results
- Raisio plc (0CIJ.L) Income Statement Analysis – Financial Results
ZIVO Bioscience, Inc. (ZIVO)
About ZIVO Bioscience, Inc.
ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 27.65K | 0.00 | 0.00 | 20.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 103.89K | 82.73K | 79.14K | 176.90K | 161.34K | 297.30K | 95.97K | 49.06K | 1.68K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 16.04K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 138.25K | 51.81K | 63.69K | 130.04K | 167.92K | 252.88K | 191.66K | 75.28K | 1.86K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 11.61K | 0.00 | 0.00 | 20.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -34.36K | 30.92K | 15.45K | 46.87K | -6.58K | 44.42K | -95.70K | -26.23K | -183.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 41.99% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -33.07% | 37.37% | 19.52% | 26.49% | -4.08% | 14.94% | -99.72% | -53.46% | -10.89% | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.38M | 2.24M | 2.12M | 3.75M | 2.31M | 2.81M | 2.38M | 788.97K | 1.03M | 1.97M | 1.02M | 677.49K | 377.89K | 395.57K | 339.32K | 148.83K | 323.19K | 333.28K | 118.11K | 192.37K | 55.71K | 0.00 | 0.00 | 0.00 |
| General & Administrative | 5.90M | 6.49M | 6.93M | 4.82M | 6.05M | 3.32M | 3.95M | 2.70M | 2.02M | 1.59M | 2.09M | 1.40M | 1.51M | 3.60M | 2.10M | 898.90K | 1.75M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 198.63K | 0.00 | 0.00 | 13.73K | 96.79K | 225.13K | 209.19K | 159.15K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.90M | 6.49M | 6.93M | 4.82M | 6.05M | 3.32M | 3.95M | 2.70M | 2.02M | 1.79M | 2.09M | 1.40M | 1.53M | 3.70M | 2.33M | 1.11M | 1.90M | 3.55M | 2.97M | 3.62M | 484.93K | 3.43K | 0.00 | 0.00 |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 652.50K | 0.00 | 0.00 | -582.00 | 0.00 | 15.00K | 0.00 | 0.00 | 2.06K | 3.61K |
| Operating Expenses | 7.27M | 8.73M | 9.05M | 8.58M | 8.35M | 6.13M | 6.33M | 3.49M | 3.06M | 3.76M | 3.11M | 2.08M | 1.90M | 4.09M | 2.67M | 1.26M | 2.23M | 3.88M | 3.08M | 3.83M | 540.63K | 3.43K | 2.06K | 3.61K |
| Cost & Expenses | 7.29M | 8.73M | 9.05M | 8.58M | 8.35M | 6.13M | 6.33M | 3.49M | 3.06M | 3.76M | 3.11M | 2.08M | 2.04M | 4.14M | 2.73M | 1.39M | 2.40M | 4.14M | 3.28M | 3.91M | 542.50K | 3.43K | 2.06K | 3.61K |
| Interest Income | 0.00 | 13.32K | 233.28K | 550.05K | 3.16M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.24K | 6.77K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 514.17K | 13.32K | 233.28K | 550.05K | 3.16M | 8.10M | 1.83M | 986.19K | 720.71K | 589.57K | 4.49M | 896.97K | 47.11K | 13.96K | 5.75K | 9.34K | 38.94K | 73.51K | 77.62K | 1.31K | 0.00 | -3.43K | -2.06K | -3.61K |
| Depreciation & Amortization | 0.00 | 4.00 | -407.49K | 8.56M | 8.35M | 18.75K | 18.75K | 25.00K | 25.00K | 29.84K | 25.69K | 74.81K | 92.40K | 37.53K | 99.58K | 33.54K | 112.81K | 632.00K | 448.59K | 15.53K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -7.26M | -8.73M | -9.05M | -550.05K | -8.35M | -6.13M | -6.33M | -3.49M | -3.06M | -5.15M | -3.11M | -2.08M | -1.94M | -4.02M | -2.62M | -1.18M | -2.12M | -3.21M | -2.73M | -3.84M | -540.82K | -3.43K | -2.06K | -3.61K |
| EBITDA Ratio | -26,267.67% | 0.00% | 0.00% | -42,778.38% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -294.94% | -1,179.88% | -4,796.11% | -329.03% | -1,379.45% | -1,201.57% | -63.92% | -7,831.89% | -32,191.49% | 0.00% | 0.00% | 0.00% |
| Operating Income | -7.26M | -8.73M | -9.05M | -8.56M | -8.35M | -6.13M | -6.33M | -3.49M | -3.06M | -5.15M | -3.11M | -2.08M | -1.94M | -4.06M | -2.65M | -1.21M | -2.23M | -3.84M | -3.18M | -3.86M | -540.82K | -3.43K | -2.06K | -3.61K |
| Operating Income Ratio | -26,267.67% | 0.00% | 0.00% | -42,778.38% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,865.71% | -4,909.09% | -3,352.50% | -684.02% | -1,385.08% | -1,291.33% | -3,313.23% | -7,863.55% | -32,191.49% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -514.17K | -13.32K | -110.76K | -550.05K | -3.16M | -8.50M | -3.71M | -2.57M | -2.73M | 5.83M | -6.99M | -1.17M | -793.30K | -3.05M | 1.24M | -594.44K | -16.31K | 365.15K | -2.67M | 0.00 | 540.82K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -7.78M | -8.75M | -9.16M | -9.11M | -11.51M | -14.64M | -10.04M | -6.06M | -5.79M | 680.81K | -10.10M | -3.25M | -3.48M | -7.11M | -1.41M | -1.80M | -2.13M | -3.47M | -5.85M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -28,127.25% | 0.00% | 0.00% | -45,528.65% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -3,347.55% | -8,592.94% | -1,783.05% | -1,020.05% | -1,320.78% | -1,168.51% | -6,095.09% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -4.00 | 233.28K | 550.05K | 3.16M | 407.49K | 1.66M | 1.40M | 1.83M | -5.20M | 2.50M | 270.85K | 2.29M | 6.09M | -2.48M | 1.19M | -126.38K | -736.49K | 5.37M | 1.31K | 540.82K | 3.43K | 2.06K | 3.61K |
| Net Income | -7.78M | -8.75M | -9.40M | -9.66M | -14.67M | -14.64M | -10.04M | -6.06M | -5.79M | 680.81K | -10.10M | -3.25M | -2.73M | -7.12M | -1.42M | -1.81M | -2.25M | -3.54M | -5.96M | -3.86M | -540.82K | -3.43K | -2.06K | -3.61K |
| Net Income Ratio | -28,127.25% | 0.00% | 0.00% | -48,278.92% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,629.30% | -8,609.82% | -1,790.32% | -1,025.33% | -1,395.18% | -1,191.15% | -6,207.23% | -7,866.21% | -32,191.49% | 0.00% | 0.00% | 0.00% |
| EPS | -4.60 | -5.58 | -7.40 | -11.41 | -25.47 | -44.84 | -34.60 | -21.73 | -21.22 | 1.79 | -43.20 | -15.38 | -2.26 | -6.54 | -1.54 | -2.77 | -4.25 | -8.26 | -26.13 | -27.12 | -4.49 | -0.18 | -0.22 | -0.39 |
| EPS Diluted | -4.60 | -5.57 | -7.39 | -11.41 | -25.47 | -44.84 | -34.60 | -21.73 | -21.22 | 1.79 | -43.19 | -15.38 | -2.26 | -6.54 | -1.54 | -2.77 | -4.25 | -8.26 | -26.13 | -27.12 | -4.49 | -0.18 | -0.22 | -0.39 |
| Weighted Avg Shares Out | 1.69M | 1.57M | 1.27M | 846.21K | 575.83K | 326.41K | 290.09K | 278.84K | 272.80K | 379.59K | 233.70K | 211.25K | 1.21M | 1.09M | 920.65K | 655.39K | 529.93K | 428.93K | 227.95K | 142.31K | 120.34K | 18.56K | 9.28K | 9.28K |
| Weighted Avg Shares Out (Dil) | 1.69M | 1.57M | 1.27M | 846.21K | 575.83K | 326.41K | 290.09K | 278.84K | 272.80K | 379.59K | 233.78K | 211.25K | 1.21M | 1.09M | 920.65K | 655.39K | 529.93K | 428.93K | 227.95K | 142.31K | 120.34K | 18.56K | 9.28K | 9.28K |
ZIVO Stock: Why It Substantially Increased Today
The stock price of Zivo Bioscience Inc (NASDAQ: ZIVO) increased by over 90% during intraday trading this morning. This is why it happened.
ZIVO Stock Price Surges Over 100% Pre-Market
The stock price of Zivo Bioscience Inc (NASDAQ: ZIVO) increased by over 100% pre-market today. These are the details.
Zivo Bioscience, Inc. Announces Pricing of Upsized $13.8 Million Public Offering and Up-listing to Nasdaq
KEEGO HARBOR, Mich., May 27, 2021 (GLOBE NEWSWIRE) -- Zivo Bioscience, Inc. (OTCMKTS:ZIVO) a biotech/agtech R&D company engaged in the development and commercialization of nutritional/nutraceutical product candidates originally derived from proprietary algal cultures, today announced the pricing of its upsized...
ZIVO Bioscience Announces US Patent Office Notice of Allowance for Administration of Proprietary Algal Biomass to Support Immune Health
KEEGO HARBOR, Mich., April 26, 2021 (GLOBE NEWSWIRE) -- ZIVO Bioscience, Inc. (OTCMKTS:ZIVO) a biotech/agtech R&D company engaged in the development and commercialization of nutritional/nutraceutical product candidates originally derived from proprietary algal cultures, announces today the US Patent Office has...
ZIVO Bioscience to Participate in Maxim Group's Inaugural Emerging Growth Virtual Conference
KEEGO HARBOR, Mich., March 11, 2021 (GLOBE NEWSWIRE) -- ZIVO Bioscience, Inc. (OTCQB: ZIVO), a biotech/agtech R&D company engaged in the development and commercialization of therapeutic and additive product candidates originally derived from proprietary algal cultures, announces that CEO Andrew A....
ZIVO Bioscience Successfully Confirms Poultry Growth Promotion and Feed Conversion Ratio Improvements in Typical Production Environments
KEEGO HARBOR, MI / ACCESSWIRE / January 11, 2021 / ZIVO Bioscience, Inc. (OTCQB:ZIVO) a biotech/agtech R&D company engaged in the development and commercialization of therapeutic/additive product candidates originally derived from proprietary algal cultures, announces today that in its recent...
Source: https://incomestatements.info
Category: Stock Reports